Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide
- PMID: 15337698
- DOI: 10.1161/01.CIR.0000141802.29945.34
Natriuretic peptide receptor-C regulates coronary blood flow and prevents myocardial ischemia/reperfusion injury: novel cardioprotective role for endothelium-derived C-type natriuretic peptide
Abstract
Background: Ischemia/reperfusion (I/R) injury complicates myocardial infarction and stroke by exacerbating tissue damage and increasing risk of mortality. We have recently identified C-type natriuretic peptide (CNP) as an endothelium-derived hyperpolarizing factor in the mesenteric resistance vasculature and described a novel signaling pathway involving activation of natriuretic peptide receptor C (NPR-C), which plays a pivotal role in the regulation of local blood flow. We tested the hypothesis that CNP/NPR-C signaling is a novel regulatory pathway governing coronary blood flow and protecting against I/R injury.
Methods and results: CNP and (Cys18)-atrial natriuretic factor (4-23) amide (cANF(4-23)) elicited dose-dependent decreases in coronary perfusion pressure (CPP) that were blocked by Ba(2+) and ouabain in the isolated Langendorff rat heart. The endothelium-dependent vasodilator acetylcholine elicited the release of CNP from the coronary endothelium. CNP and cANF(4-23) reduced infarct size after 25 minutes of global ischemia and 120 minutes of reperfusion, maintaining CPP and left ventricular pressure at preischemic values. The vasorelaxant and protective activity of CNP and cANF(4-23) were enhanced in the absence of endothelium-derived nitric oxide.
Conclusions: Endothelium-derived CNP is involved in the regulation of the coronary circulation, and NPR-C activation underlies the vasorelaxant activity of this peptide. Moreover, this newly defined pathway represents a protective mechanism against I/R injury and a novel target for therapeutic intervention in ischemic cardiovascular disorders.
Similar articles
-
Definitive role for natriuretic peptide receptor-C in mediating the vasorelaxant activity of C-type natriuretic peptide and endothelium-derived hyperpolarising factor.Cardiovasc Res. 2007 Jun 1;74(3):515-25. doi: 10.1016/j.cardiores.2007.02.032. Epub 2007 Mar 3. Cardiovasc Res. 2007. PMID: 17391657 Free PMC article.
-
Vascular natriuretic peptide receptor-linked particulate guanylate cyclases are modulated by nitric oxide-cyclic GMP signalling.Br J Pharmacol. 2003 Aug;139(7):1289-96. doi: 10.1038/sj.bjp.0705365. Br J Pharmacol. 2003. PMID: 12890708 Free PMC article.
-
C-type natriuretic peptide inhibits L-type Ca2+ current in rat magnocellular neurosecretory cells by activating the NPR-C receptor.J Neurophysiol. 2005 Jul;94(1):612-21. doi: 10.1152/jn.00057.2005. Epub 2005 Mar 16. J Neurophysiol. 2005. PMID: 15772242
-
C-type natriuretic peptide: the endothelial component of the natriuretic peptide system.J Cardiovasc Pharmacol. 1998;32 Suppl 3:S22-8. J Cardiovasc Pharmacol. 1998. PMID: 9883743 Review.
-
C-type natriuretic peptide in vascular physiology and disease.Pharmacol Ther. 2005 Feb;105(2):85-93. doi: 10.1016/j.pharmthera.2004.08.011. Pharmacol Ther. 2005. PMID: 15670620 Review.
Cited by
-
Tuscany Sangiovese grape juice imparts cardioprotection by regulating gene expression of cardioprotective C-type natriuretic peptide.Eur J Nutr. 2020 Oct;59(7):2953-2968. doi: 10.1007/s00394-019-02134-x. Epub 2019 Nov 9. Eur J Nutr. 2020. PMID: 31707544
-
Evidence against C-type natriuretic peptide as an arterial 'EDHF'.Br J Pharmacol. 2008 Jan;153(1):4-5. doi: 10.1038/sj.bjp.0707520. Epub 2007 Oct 29. Br J Pharmacol. 2008. PMID: 17965742 Free PMC article.
-
C-Type Natriuretic Peptide Improves Left Ventricular Functional Performance at Rest and Restores Normal Exercise Responses after Heart Failure.J Pharmacol Exp Ther. 2016 Jun;357(3):545-53. doi: 10.1124/jpet.115.231696. Epub 2016 Mar 29. J Pharmacol Exp Ther. 2016. PMID: 27026682 Free PMC article.
-
Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure.Circ Heart Fail. 2013 May;6(3):594-605. doi: 10.1161/CIRCHEARTFAILURE.112.000289. Circ Heart Fail. 2013. PMID: 23694773 Free PMC article. Review. No abstract available.
-
C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target.Curr Pharm Des. 2010;16(37):4080-8. doi: 10.2174/138161210794519237. Curr Pharm Des. 2010. PMID: 21247399 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases